This study included treatment with and without temozolomide (TMZ) in patients with first or second confirmed GBM recurrence harboring tumors with high EGFR amplification levels, as well as the immunoreactivity of EGFRvIII or absence of PTEN [97,99]. The gene discussed is EGFR; the disease is glioblastoma.